Page last updated: 2024-11-02

pd 153035 and von Hippel-Lindau Disease

pd 153035 has been researched along with von Hippel-Lindau Disease in 1 studies

4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source
PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.

von Hippel-Lindau Disease: An autosomal dominant disorder caused by mutations in a tumor suppressor gene. This syndrome is characterized by abnormal growth of small blood vessels leading to a host of neoplasms. They include HEMANGIOBLASTOMA in the RETINA; CEREBELLUM; and SPINAL CORD; PHEOCHROMOCYTOMA; pancreatic tumors; and renal cell carcinoma (see CARCINOMA, RENAL CELL). Common clinical signs include HYPERTENSION and neurological dysfunctions.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Paulsen, N1
Brychzy, A1
Fournier, MC1
Klausner, RD1
Gnarra, JR1
Pause, A1
Lee, S1

Other Studies

1 other study available for pd 153035 and von Hippel-Lindau Disease

ArticleYear
Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Feb-13, Volume: 98, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Cell Division; Cell Hypoxia; Enzyme Inhibitors; ErbB Receptors; Gene Exp

2001